Troglitazone, a PTP1B inhibitor [13], which is a member of the thiazolidinedione (TZD) compounds, already has been forbidden to be used for the treatment of diabetes in clinical situations in recent years due to its side effects and toxicity [14,15]. The gene discussed is PTPN1; the disease is diabetes mellitus.